Clinical results with estramustine phosphate (NSC-89199): a comparison of the intravenous and oral preparations.
The clinical results with estramustine phosphate in far-advanced carcinoma of the prostate refractory to other treatments are presented. Good clinical results have been achieved in about 40 percent of the 90 patients treated and regression of metastases has occurred in about 20 percent. Estramustine phosphate in the primary treatment of far-advanced carcinoma of the prostate shows very good and promising clinical results. A total of 132 patients were treated.
D000135:Acid Phosphatase / Q000097:blood; D000284:Administration, Oral; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004961:Estramustine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009362:Neoplasm Metastasis; D009365:Neoplasm Regression, Spontaneous; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D000135:Acid Phosphatase